Michael Mack, M.D. Dallas, TX February 21, 2010

Slides:



Advertisements
Similar presentations
” سبحانك لا علم لنا إلا ما علمتنا إنك أنت العليم الحكيم “
Advertisements

C hinese D atabase for C ardiovascular S urgery Questions and Thoughts Shengshou Hu M.D. President, Cardiovascular Institute & Fuwai Hospital Director,
IRB PRESENTATION REGULATORY PATHWAYS HDE – PMA William Hellenbrand MD Director – Pediatric Cardiology Columbia University College of Physicians & Surgeons.
Long-Term Outcomes Using a Self- Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery: Two-Year Results From.
Use of Psoas Muscle Size as a Frailty Assessment Tool for Open and Transcatheter Aortic Valve Replacement Raghavendra Paknikar BS Jeffrey Friedman BS David.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
ACHA Policy Advisory Council March 15, Public Reporting  Jeffrey Bott, MD, MBA President of the Florida Society of Cardiovascular and Thoracic.
Validation of Mayo Clinic Risk Adjustment Model for In-Hospital Mortality following Percutaneous Coronary Interventions using the National Cardiovascular.
Patterns of red blood cell transfusion use and outcomes in patients undergoing percutaneous coronary intervention in contemporary clinical practice: Insights.
The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries Dr. Christian Finley MD MPH FRCSC McMaster University.
Bariatric Surgery: Outcomes and Safety MISS 2010 Bruce M. Wolfe, MD Professor of Surgery Oregon Health & Science University.
Lessons Learned from the Society of Thoracic Surgeons (STS) Congenital Database September 25, 2015 Robert J. Dabal, MD Associate Professor of Surgery.
Aortic Stenosis -The Unmet Need Simon Ray University Hospitals of South Manchester ACI 2009.
INTERNATIONAL. CAUTION: For distribution only in markets where CoreValve® is approved. Not for distribution in U.S., Canada or Japan. Medtronic, Inc
Cardiovascular Consortium Effective Health Care Program Art Sedrakyan, MD, PhD Center for Outcomes & Evidence, AHRQ.
Incidence and Outcomes of Valve Hemodynamic Deterioration in Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: A Report from the Society.
Greater New York Geriatric Cardiology Consortium: Valve Disease in Older Adults Allan Schwartz, MD Columbia University Medical Center New York Presbyterian.
Lessons from PARTNER I (A & B) CRT, Washington DC, Feb 5, 2012
Patients the Surgeon Should Refer for TAVR
Outcomes in the CoreValve US High-Risk Pivotal Trial in Patients with a Society of Thoracic Surgeons Predicted Risk of Mortality Less than or Equal to.
Patients at intermediate surgical risk undergoing isolated interventional or surgical aortic valve replacement for severe symptomatic aortic valve stenosis.
What should be the optimal Design for TAVI Procedure.
Patient Eligibility for Commercial TAVR in the US
Extending the Boundaries of TAVR: Future Directions
Clinical Trial Design for Second Generation TAVI - Academic View
Todd M. Dewey, MD, David L. Brown, MD, Tony S. Das, MD, William H
Anita W. Asgar MD, FRCPC, FACC Montreal Heart Institute
Raj R. Makkar, MD On behalf of The PARTNER Trial Investigators
Are we ready to perform TAVI in Intermediate Risk Patients?
Updates From NOTION: The First All-Comer TAVR Trial
J. Matthew Brennan, MD, MPH Duke University School of Medicine
Are we ready for expanding TAVI indications to moderate and low risk
Adherence to the Labeling
Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.
Review of the Latest OUS Data from the Self-Expanding Valve Studies
The Spanish Data Bank PEGASO M. Martínez-Sellés
PCI related in-hospital mortality based on race and gender in the USA
Ruyun Jin, MD, Gary L. Grunkemeier, PhD, Albert Starr, MD 
TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.
University of Pennsylvania
Giuseppe Tarantini MD, PhD
Updates From SURTAVI in Intermediate Risk Patients
Insights from the NCDR® STS/ACC TVT Registry.
Niv Ad, MD Chief, Cardiac Surgery Professor of Surgery, VCU
Axel Linke University of Leipzig Heart Center, Leipzig, Germany
Annual Outcomes With Transcatheter Valve Therapy
University Heart Center Hamburg
Balloon-Expandable Transcatheter Valve System : OUS Data
Annual Outcomes With Transcatheter Valve Therapy
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Cardiovacular Research Technologies
Current UK and EACTS database initiatives
Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
Sorin Bicarbon: 17 years of clinical use
Advising complex patients who require complex heart operations
Reply The Annals of Thoracic Surgery
Society of Thoracic Surgeons Score Is Superior to the EuroSCORE Determining Mortality in High Risk Patients Undergoing Isolated Aortic Valve Replacement 
Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: Changes in risks, valve types, and outcomes in the Society.
Shikhar Agarwal, MD, MPH, Aatish Garg, MD, Akhil Parashar, MD, Lars G
A decade of change—risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990–1999: a report from the STS National Database.
Ruyun Jin, MD, Gary L. Grunkemeier, PhD, Albert Starr, MD 
The relative performance characteristics of the logistic European System for Cardiac Operative Risk Evaluation score and the Society of Thoracic Surgeons.
Sergey Leontyev, MD, Thomas Walther, MD, PhD, Michael A
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
No Financial Disclosure or Conflict of Interest
Tom Kai Ming Wang, MBCHB, David H. M
Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement  Todd M. Dewey,
Todd M. Dewey, MD, David L. Brown, MD, Tony S. Das, MD, William H
Racing to the Rubicon  Michael J. Reardon, MD, Vinod H. Thourani, MD 
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

Michael Mack, M.D. Dallas, TX February 21, 2010 Determining the Surgical Risk Stratification in Aortic Stenosis: STS, EuroSCORE, and “Frailty” Assessments Michael Mack, M.D. Dallas, TX February 21, 2010

Michael J. Mack, MD DISCLOSURES Consulting Fees Edwards Lifesciences LLC, MAQUET GmbH & Co. KG, Medtronic CardioVascular, Inc. I intend to reference unlabeled/ unapproved uses of drugs or devices in my presentation. I intend to reference Percutaneous Heart valves.

Aortic Valve Surgery Predictive Risk Algorithms STS EuroSCORE (additive) EuroSCORE (logistic) Ambler (UK) Northern New England New York State Providence Health System

Do any of these algorithms accurately predict risk in patients undergoing TAVI ?

> 20 33% 12.5% <10 7.3% 7.5% 10-20 13.7% 12.6% LES Mean LES 30day/ Hosp Mortality <10 7.3% 7.5% 10-20 13.7% 12.6% > 20 33% 12.5%

STS LES >90th Percentile 13.3% (8.38-46.8) 50.87 (33.47-93.32) Observed 18.75% 15.63% O/E Ratio 1.41 0.31 N= 638

LES 8.46% 13.9% 28.5% All LES 10-20 LES >20 n 652 130 52 Observed Mortality 2.5% 4.6% 3.9% LES 8.46% 13.9% 28.5% STS 4.4% 6.5% 10.1%

European Journal of Cardio-thoracic Surgery 37 (2010) 255—260

European Journal of Cardio-thoracic Surgery 37 (2010) 255—260

Conclusions: EuroSCORE appears to be an invalid model in absolute and relative risk prediction for isolated AVR

“Hence, why is the logistic EuroSCORE, which by all accounts gives the highest values and is the furthest away from observed rates, used almost exclusively by the groups performing PAVI, when it has been conclusively proven to be inaccurate, unreliable and difficult to validate for all groups of patients?” Manuel Antunes

Logistic Euroscore in Surgical AVR LES Predicted Observed DiGiammarco 379 9.4% 5.2% German Society 6,305 7.3% 3.9% Kalavrouziotis 1,421 3.2% LES over predicts AVR mortality by 1.5-2X

Logistic Euroscore in High Risk (LES >20) Surgical AVR LES Predicted Observed Leontyev 33 12.5 Brown 23.6 5.8 Dewey 50.8 15.6 Wendt 28.5 3.9 Kalavrouziotis 38.7% 11.4% LES over predicts mortality in high risk AVR by 3-7X

Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database Started in 1986 in response to HCFA (CMS) public reporting of non risk adjusted outcomes of cardiac surgery Outcomes from 1,000 centers 90% of all cardiac surgery providers in U.S. 3.6 million procedures Warehoused and managed by DCRI

Society of Thoracic Surgeons Adult Cardiac Surgery Database NQF endorsed Audited Predicts Mortality and 8 other endpoints Data shared with 5 major payors Public reporting in 2010 Linkage to SS Death Masterfile and CMS Harmonization with ACC Database

STS Aortic Valve Risk Algorithm Valves only- 2002-2006 N= 67,292 Aortic Valve Operations 60% Development Sample/40% Validation 24 covariates for mortality C-index 0.799 for mortality

EuroSCORE Risk Algorithm Developed in Europe All cardiac operations Additive 14,871 patients in 128 centers in 8 countries between Sept and November 1995 Logistic-LES 14,799 patients in 1995- published 2003

Risk Algorithms LES STS Population Analyzed 1995 2002-2006 Place Europe (8 countries) US Number Operations 14,799 67,292 Type of Operations All cardiac Aortic Valve only Covariates for Aortic Valve Mortality 12 24

Risk Factors Not Included in Algorithms Data not collected or too few patients with variables to validate Liver disease Porcelain aorta Frailty Radiation Dementia/Parkinson’s

LES OBSERVED STS

What Does This Mean? LES- the TAVI is better than expected STS- the TAVI is worse than predicted Neither apply since these are different patients (inoperable) and the algorithms aren’t accurate at the extreme risk LES STS OBSERVED

2 Females > 85 years, STS>10 One operable, one NOT !

Age Gender Functional Ability Co-Morbidities Bathing Diabetes Walking Lung Disease CHF Active Tobacco Use BMI Functional Ability Functional Ability Bathing Walking Managing Finances Pushing Large Objects

Score 4 Year Mortality 0-5 <4% 6-9 15% 10-13 42% >14 64%

Summary Both STS and LES are fairly accurate for predictive value in low risk patients STS is more accurate especially in high risk: Larger database- 67K vs. 14K More specific – AVR only vs.all cardiac More variables collected- 24 vs.12 More current- by 10 years US population LES should not be used for predicting risk If used needs to be with a “recalibration coefficient” of 0.3-0.5

Logistic Euroscore should no longer be used for predicting risk or evaluating outcomes in TAVI patients! The evidence of inaccuracy in high risk AVR patients is overwhelming It gives a false sense that outcomes of TAVI are better than they are There is no valid excuse not to use STS risk algorithm Most accurate Online user friendly Free

National Disease-based Registry of Valvular Heart Disease Linkage of: Response to RFA-HS-10-005 ARRA-AHRQ Recovery Act 2009 Limited Competition PROSPECT Studies Building New Clinical Infrastructure for Comparative Effectiveness Research February 16, 2010 National Disease-based Registry of Valvular Heart Disease Linkage of: STS Adult Cardiac Database ACCF NCDR Database Social Security Death Masterfile Medicare Parts A and B Claims Database Direct Comparison of Clinical Outcomes of: Medical Therapy TAVI Surgery

The FDA GOT THIS ONE RIGHT 6 YEARS AGO